TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30184110
Drug: JNJ‐9375 (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐9375 (2.5, 25, and 250 μg/mL)
Study: 30184110
Drug: Bivalirudin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (6 μg/mL)
Study: 21787883
Drug: Ovulation induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation induction (OI) with aromatase inhibitor
Study: 19340902
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of oral allopurinol at 15 h and 3 h before ERCP
Study: 19340902
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo at the same times as the allopurinol group
Study: 15103755
Drug: Serum concentration
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum concentration of prolactin before treatment in hyperprolactinemic patients
Study: 9146905
Drug: Sugar alcohols
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar alcohols (polyols) in aqueous solutions
Study: 7712903
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + misoprostol 600 micrograms (Group 1)
Study: 7712903
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + PG05 1 mg vaginal suppository (Group 2)
Study: 24200748
Drug: Losartan (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50mg daily for 4 weeks)
Study: 24200748
Drug: Trichlormethiazide (4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide (4mg daily for 4 weeks)
Study: 23332861
Drug: FF 200
Normalized name: guaifen/pe/acetaminophen/caff 200 mg-10 mg-325 mg-32.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 200 μg
Study: 21715530
Drug: Duloxetine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (120 mg)
Study: 19228745
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine alone (arm A)
Study: 19228745
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine + GM-CSF (arm B)
Study: 19228745
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine + IFN-alpha2b (arm C)
Study: 19228745
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine + IFN-alpha2b + GM-CSF (arm D)
Study: 19228745
Drug: Vaccine immune
Normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine immune response
Study: 10684783
Drug: Alcohol (0.34,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.34, 0.68, and 1.02 g/kg)
Study: 8364943
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 0.075% cream
Study: 8364943
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 0.075% cream (long-term phase)
Study: 29897249
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg once-daily)
Study: 29897249
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide alone
Study: 24495204
Drug: Couples treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples treatment
Study: 24495204
Drug: Individuals treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals treatment
Study: 23539727
Drug: Levothyroxine (L-T₄)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T₄)
Study: 16192761
Drug: Org 25969
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25969 (8 mg/kg)
Study: 16192761
Drug: Org 25969
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25969 (0.1-8.0 mg/kg)
Study: 12905476
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg every 6 weeks after induction phase)
Study: 7892316
Drug: Rapid expansion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid expansion starting 1 week postoperatively on a daily basis; expansion period of 14 days.
Study: 29779802
Drug: Trophic feeds
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophic feeds (10‐20 ml/kg/day) starting 4‐6 hours after surgery
Study: 21749488
Drug: Supplement containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement containing 10 mg of ferrous sulphate
Study: 15777442
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulphate 80 mg daily
Study: 7547822
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of 100 g/l Intralipid (8.36 kJ/min)
Study: 7547822
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (9 g NaCl/l)
Study: 2389909
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 0.2 mg inhaled three times a day for 2 months
Study: 2389909
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled three times a day for 2 months
Study: 2389909
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) treatment withheld after second antigen provocation
Study: 25590523
Drug: sTM levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTM levels at enrollment (highest quartile > 14 ng/mL vs. lowest quartile < 7 ng/mL)
Study: 25590523
Drug: Syndecan‐1 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syndecan‐1 levels at enrollment (> 240 vs. < 70 ng/mL)
Study: 24024727
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (ropinirole 0.25 mg/d)
Study: 21338496
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (378 mg/day) and theanine (210 mg/day)
Study: 8040671
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with cisplatin and fluorouracil (5‐FU) followed by radiation therapy
Study: 8040671
Drug: Standard surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgery followed by radiation therapy
Study: 4880259
Drug: Hypnosis (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (monthly sessions and daily autohypnosis for one year)
Study: 28000127
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure-lowering treatment (target SBP <140 mmHg within 1 hour)
Study: 28000127
Drug: Guideline-recommended blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended blood pressure-lowering treatment (target SBP <180 mmHg)
Study: 26362235
Drug: Corticosteroid (Steroid)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (Steroid) injection
Study: 18280832
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy measures (feeding modifications, positioning, tobacco smoke avoidance)
Study: 16556888
Drug: Consolidation/maintenance chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation/maintenance chemotherapy
Study: 11194431
Drug: Ropivacaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (200 mg)
Study: 8791948
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d.
Study: 8791948
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d. plus Clarithromycin 250 mg b.d.
Study: 1620416
Drug: Intravenous phosphocreatine
Normalized name: phosphocysteamine
DrugBank: Phosphocysteamine (DB17640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phosphocreatine administered after induction of anaesthesia, prior to cardiac arrest and after release of aortic cross-clamp
Study: 1620416
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group A)
Study: 28831717
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment (until hospital discharge)
Study: 25934015
Drug: External counterpulsation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External counterpulsation (ECP) treatment, 35 daily 1 hour sessions
Study: 21880037
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Study: 21880037
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (SO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Study: 21880037
Drug: Saline, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Study: 9809934
Drug: Myocardial contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial contrast echocardiography (MCE) using bolus doses of a perfluorocarbon‐filled contrast agent (NC100100)
Study: 9809934
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of wall motion and MCE assessment
Study: 7661162
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with bismuth, metronidazole, and tetracycline (BMT) for 1 week
Study: 7661162
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with sucralfate, metronidazole, and tetracycline (SMT) for 1 week
Study: 6990320
Drug: Co-trimazine (sulphadiazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimazine (sulphadiazine 410 mg and trimethoprim 90 mg 12-hourly)
Study: 6990320
Drug: Co-trimoxazole (sulphamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (sulphamethoxazole 800 mg and trimethoprim 160 mg 12-hourly)
Study: 6990320
Drug: Sulphamethizole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphamethizole (1 g 8-hourly)
Study: 29492753
Drug: App+Reminder (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: App+Reminder (weekly reminders to use app)
Study: 25902387
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (IVA) preoperatively
Study: 25902387
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (IVA) within 30 minutes of surgery
Study: 22889730
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (15 g protein at breakfast and lunch)
Study: 15244109
Drug: Stressen (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stressen (twice daily for 30 days)
Study: 2532102
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin injection treatment
Study: 2532102
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (CSII and injections)
Study: 59150
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate 320 mg
Study: 31221872
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive (a chance to get shopping points) for increasing daily steps
Study: 27269410
Drug: Intravenous ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferrous sucrose (up to three calculated replacement doses)
Study: 27269410
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (150 mg twice daily for six weeks)
Study: 25831420
Drug: 9-valent human
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent human papillomavirus (9vHPV) vaccine administered concomitantly with REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Study: 25831420
Drug: REPEVAX (diphtheria,
Approvals — FDA: no, EMA: no, PMDA: no
Description: REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Study: 25831420
Drug: Nonconcomitant vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonconcomitant vaccination group (REPEVAX administered at month 1)
Study: 23724225
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg inhaled budesonide
Study: 23724225
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg prednisolone orally daily
Study: 23724225
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (for budesonide trial)
Study: 11110928
Drug: Pulse-spray thrombolysis
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-spray thrombolysis
Study: 11110928
Drug: Thrombus treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombus treatment time for thrombectomy
Study: 11110928
Drug: Thrombus treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombus treatment time for thrombolysis
Study: 2581324
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg 3 times a day
Study: 27612525
Drug: Corticosteroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone 32 mg)
Study: 27612525
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (methylprednisolone 32 mg and meloxicam 15 mg)
Study: 27612525
Drug: NSAIDs (meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (meloxicam 15 mg)
Study: 21696732
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of amoxicillin clavulanate
Study: 18224344
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitors for mild IgA nephropathy
Study: 18224344
Drug: Steroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids for severe IgA nephropathy
Study: 17194243
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (Cr) supplementation at a dose of 0.3 g.kg(‐1) for the initial 7 days and 0.03 g.kg(‐1) for subsequent 9 weeks
Study: 17194243
Drug: Placebo (Pl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pl) at a dose of 0.3 g.kg(‐1) for the initial 7 days and 0.03 g.kg(‐1) for subsequent 9 weeks
Study: 14989126
Drug: Multimodality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality treatment including IORT
Study: 14989126
Drug: Multimodality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality treatment without IORT
Study: 8756734
Drug: Clostilbegyt treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostilbegyt treatment (50 mg daily for 240 days)
Study: 1818002
Drug: Gallopamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (50 mcg/Kg over 5 min)
Study: 27262086
Drug: Sarcosine (2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2g daily)
Study: 19188900
Drug: Non-specific oral
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific oral advice to increase physical activity
Study: 15799006
Drug: Hebervital (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hebervital (formulation A)
Study: 15799006
Drug: Neupogen (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neupogen (formulation B)
Study: 12002769
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus granulocyte colony-stimulating factor
Study: 12002769
Drug: Prior chemotherapy
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior chemotherapy courses
Study: 12002769
Drug: Disease status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease status or mobilizing regimen dose
Study: 6136432
Drug: morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (10 mg)/droperidol (2.5 mg)/atropine (0.3 mg)
Study: 6136432
Drug: pethidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: pethidine (100 mg)/droperidol (2.5 mg)/atropine (0.3 mg)
Study: 6136432
Drug: pethidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: pethidine (100 mg)/droperidol (2.5 mg)
Study: 31727024
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + 12-weekly ipilimumab
Study: 31727024
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + 3-weekly ipilimumab
Study: 25934864
Drug: (−)‐epicatechin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)‐epicatechin (100 mg/d)
Study: 25934864
Drug: quercetin‐3‐glucoside (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: quercetin‐3‐glucoside (160 mg/d)
Study: 21195961
Drug: Warmed saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed saline solution (37.5°C)
Study: 21195961
Drug: Room-temperature saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room-temperature saline solution
Study: 18844082
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg soy isoflavone and 440 mg Ca and 100 IU VD supplement/d (n = 26)
Study: 18844082
Drug: 440 mg
Normalized name: placebo 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 440 mg Ca and 100 IU VD supplement/d (n = 26)
Study: 16580392
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) therapy for 3 months
Study: 16580392
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) therapy
Study: 15486831
Drug: Tafenoquine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine, 300 mg per day for 7 days (n=18)
Study: 15486831
Drug: Tafenoquine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine, 600 mg per day for 3 days (n=19)
Study: 15486831
Drug: Tafenoquine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine, 600 mg as a single dose (n=18)
Study: 15486831
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (n=13)
Study: 15486831
Drug: Primaquine base,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine base, 15 mg per day for 14 days (n=12)
Study: 1734637
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 to 100 mg)
Study: 1734637
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 to 100 mg) + Isosorbide dinitrate (ISDN) (10 mg)
Study: 6469080
Drug: Pentagastrin infusion
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentagastrin infusion (0.15 micrograms/kg/h)
Study: 6469080
Drug: Proglumide infusion
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide infusion (placebo control)
Study: 27139058
Drug: Web-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based guided self-help intervention (cognitive-behavioral and problem-solving therapy supported by an online trainer; n=202)
Study: 22786596
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management therapy for MS (SMT‐MS)
Study: 9445490
Drug: Allopurinol (ALLO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (ALLO; 40 mg/kg)
Study: 981327
Drug: Amitriptyline withdrawn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline withdrawn overtly to no medication
Study: 29267300
Drug: 2 min
Normalized name: Accu-Clear 2 Minute Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 min CC with 8 min rest (Group A)
Study: 29267300
Drug: 2 min
Normalized name: Accu-Clear 2 Minute Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 min CC with 4 min rest (Group B)
Study: 29267300
Drug: 2 min
Normalized name: Accu-Clear 2 Minute Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 min CC with 6 min rest (Group C)
Study: 29267300
Drug: 2 min
Normalized name: Accu-Clear 2 Minute Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 min CC with 8 min rest (Group D)
Study: 25921965
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (ICD)-only therapy
Study: 19371931
Drug: Orchiopexy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiopexy combined with neoadjuvant GnRH therapy (1.2 mg/d nasal spray for 4 weeks)
Study: 16750325
Drug: Once-daily chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily chest wall irradiation (60 Gy in 2-Gy q.d. fractions)
Study: 11728069
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg body weight)
Study: 8194141
Drug: Three-hourly subcutaneous
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-hourly subcutaneous bolus injections of morphine